The Killion family of Birmingham has given a $10 million gift to UAB to create the Wayne Killion Endowment for the Center for Neurodegeneration and Experimental Therapeutics and to rename the center the Killion Center for Neurodegeneration and Experimental Therapeutics.

This is a step toward an understanding of the brain that ultimately describes the mechanistic basis of human cognition and behavior.

This finding suggests that therapy to remodel synapses could help memory in old age and dementia patients.

By prohibiting the Activin A protein from functioning, researchers were able to halt the development of dyskinesia symptoms and effectively erase the brain’s “bad memory” response to L-DOPA treatments.

Multiple system atrophy is a rare and fatal neurodegenerative disease, with no known disease modifying therapy. 

In a mouse model, border-associated macrophages, not microglia, were essential for the neuroinflammation that precedes neurodegradation. Targeting this subset could be a disease-modifying therapy in neurodegenerative disease.

Record $95 million Heersink lead gift to advance strategic growth and biomedical innovation.

New results suggest the answer is no, implying that the role of tau in the pathogenesis of Lewy body dementias is distinct from Alzheimer’s disease.